(Q54631021)

1 June 2018

title

Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA. (English)

1 reference

1 June 2018

author

Michal Marzec

1

1 reference

1 June 2018

Anders Woetmann

8

1 reference

1 June 2018

author name string

X Liu

2

1 reference

1 June 2018

W Wong

3

1 reference

1 June 2018

Y Yang

4

1 reference

1 June 2018

T Pasha

5

1 reference

1 June 2018

K Kantekure

6

1 reference

1 June 2018

P Zhang

7

1 reference

1 June 2018

M Cheng

9

1 reference

1 June 2018

N Odum

10

1 reference

1 June 2018

M A Wasik

11

1 reference

1 June 2018

language of work or name

English

0 references

publication date

22 November 2010

1 reference

1 June 2018

published in

Oncogene

1 reference

1 June 2018

volume

30

1 reference

1 June 2018

issue

11

1 reference

1 June 2018

page(s)

1372-1378

1 reference

1 June 2018

https://scigraph.springernature.com/pub.10.1038/onc.2010.505

exact match

0 references

cites work

The impact of O2 availability on human cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

The anaplastic lymphoma kinase in the pathogenesis of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin's lymphomas and correlate with hypoxia inducible factor activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Targeting HIF-1 for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

The aryl hydrocarbon nuclear translocator alters CD30-mediated NF-kappaB-dependent transcription

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

The STATs of cancer--new molecular targets come of age

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Targeting STAT3 in cancer: how successful are we?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.505

31 March 2020

Identifiers

DOI

10.1038/ONC.2010.505

1 reference

1 June 2018

Dimensions Publication ID

1039299929

0 references

1 reference

1 June 2018